

COVAX


End to end story

CEPI



Why we need COVAX

With a fast-moving pandemic, no one is safe, unless everyone is safe



- US\$375 billion lost to the global economy each month
- Under a business as usual approach, it could take years to develop effective vaccines and decades to ensure they reach everyone that needs them
- Today, historic scientific collaboration, with currently over 200 vaccine candidates in varying stages of development
- Unprecedented commitment from the private sector to work together in the interests of the global public good

Our goals

- To develop the largest and most diverse actively managed portfolio of vaccine candidates so that the best vaccines are made available and the world has access to the best science
- To deliver 2 billion doses by end of 2021
- To guarantee fair and equitable access to COVID-19 vaccines for every country in the world



COVAX: an end-to-end solution

Bold ideas and brilliant innovation for the worst global health crisis in 100 years



How can COVAX secure vaccine supply

The COVAX risk-sharing approach:

Buying into a portfolio of multiple vaccine candidates allows countries to insure themselves against failure of individual vaccines and secure cost-effective access to successful vaccines

Sharing risk of development, guaranteeing volumes and building manufacturing capacity now means accessing vaccines quickly once proven successful

Active portfolio management ensures maximum return on investment and efficient use of assets as insights in individual assets and portfolio evolves

What is needed

July 2020 - December 2020
\$11.3 B

January 2021 - December 2021
\$6.8 B

Commitment of high-income and upper middle-income countries to purchase up to 950 M doses through COVAX Facility

Doses for low-income countries and lower middle-income countries to be procured through the Facility via the Gavi COVAX Advance Market Commitment

Current CEPI COVID-19 vaccine portfolio consists of 9 projects


Candidate	Location	Platform	Current Phase
AZ / Oxford	UK	Viral Vector	Phase III
Clover	China	Protein	Phase I
CureVac	Germany	RNA	Phase I
Inovio	USA	DNA	Phase I
Novavax	USA	Protein	Phase I
Moderna	USA	RNA	Phase IIa
Merck/Themis	USA/Austria	Viral Vector	Preclinical
University of Hong Kong	China	Viral Vector	Preclinical
University of Queensland	Australia	Protein	Preclinical

Speed, Scale, Access

Why we need to build manufacturing capacity now

To deliver 2 billion doses by the end of 2021, 2-3 successful programmes are needed to:

- 1 Produce early doses to support clinical studies
- 2 Scale up processes to industrial scale before clinical trials begin
- 3 Scale-out products in different countries to expand capacity
- 4 Stockpile vaccines in bulk in anticipation of dose level definition
- 5 Anticipate projects failing during clinical development
- 6 Repurpose facilities for successful products, if needed



The Allocation Framework and Allocation Mechanism has been built including your feedback


- Goal**
- Protect public health and minimize societal and economic impact by reducing COVID-19 mortality Equal allocation
 - between LICs, LMICs, UMICs and HICs as we seek to reach 20% of the population

- Priorities**
- 1 Health and social care workers**
All countries receive doses to cover 3% of their population
 - 2 High-risk adults**
All countries receive additional doses to cover a total of 20% of their population (in tranches)
 - 3 Further priority groups**
Countries receive doses to cover more than 20% of their population


- Timing**
- ← Countries receive doses proportionally to their total population →
- ← Timing is based on country need, vulnerability and COVID-19 threat →

A buffer will also be set aside for emergency deployment based on immediate needs


COVAX Facility



Why COVAX Matters



Doses for at least 20% of your population



End the acute phase of the pandemic



Diverse and actively managed portfolio of vaccines



Rebuild economies



Vaccines delivered as soon as they are available

How you can participate

Self-financing countries:

Letters sent to Missions 3 July

Deadline to Submit Letter of Interest by 10 July Self-

pay country consultation 16&17 July

Final commitments 31 Aug

AMC-supported countries:

Letters sent to Missions 6 July

Invitation to submit indication of interest ongoing AMC-

supported country consultation 20&21 July

Submission of application to join COVAX AMC Fall (tbc)

One World, Protected: This is how far we've come

Access to the world's largest and most diversified portfolio

9 candidates currently, expanding further: AZ/Oxford University, Clover Biopharma, CureVac, Inovio, Novavax, Moderna, Merck/Themis, University of Hong Kong, University of Queensland

4+ technologies: mRNA, DNA, protein, viral vector

Fastest way to get to a safe and efficacious vaccine

Manufacturing today already under way, incl. capacity build-up, preparation for tech transfers, etc.

Q4 2020 Potentially some candidates that could achieve emergency use approval

Volumes and funding secured

300+ million doses secured to date; more volume underway

\$2 billion in funding secured

Equitable global access and risk pooling

Champion equity through WHO's fair allocation framework and emergency buffer

Shared risk through pooled procurement of "COVAX Facility"

Key elements

1

COVAX pillar is an
end-to-end solution

Key elements

1

COVAX pillar is an end-to-end solution

2

All elements need to be funded in parallel for COVAX to be successful

Key elements

1

COVAX pillar is an end-to-end solution

2

All elements need to be funded in parallel for COVAX to be successful

3

The more countries participate, the higher the chances of success are

Act Now. Act Together. Act boldly to end Covid-19.

CEPI

